Where Precision Meets Compassion

Cutting-Edge Cancer Treatment for All Types — Brought Directly to You

RadiantPath Health, Inc brings PSMA-targeted radioligand therapy (Pluvicto®) directly to your patients via licensed mobile infusion units.

We are the First and Only Mobile Cancer Care Across Texas and Beyond

RadiantPath Health is redefining access to precision cancer care through mobile delivery of targeted radiopharmaceutical therapies — including FDA-approved Lutetium-177 PSMA Therapy (Pluvicto®).

We specialize in treating patients with advanced cancers — including those with PSMA-positive mCRPC — before chemotherapy.

We partner closely with
Urologists and Oncologists to
streamline patient access,
treatment coordination, and
outcome tracking.

Before and After Scan Showing Pluvicto Effectiveness in Cancer Reduction

Real patient scan: Before and after Pluvicto® therapy

Real Results. Real Hope.

RadiantPath delivers transformative outcomes across a wide range of cancers — with therapies you can see working. Pluvicto® is just one example of how targeted radiotherapy can dramatically reduce cancer burden in advanced cancers. Click the image to explore a real before-and-after scan.

See Clinical Details

Why Do We Use Pluvicto®?

✔ Expanded FDA indication (March 2025) for use prior to Chemotherapy

✔ Tripled eligible patient population

✔ 59% reduction in risk of progression or death

✔ Over 2x median rPFS vs. ARPI (11.6 vs. 5.6 months).